AstraZeneca Plc $AZN Shares Newly Acquired by Harbour Investments Inc.

Harbour Investments Inc. purchased a new stake in AstraZeneca Plc (NYSE:AZN – Free Report) in the third quarter, HoldingsChannel reports. The firm purchased 7,043 shares of the company’s stock, valued at approximately $1,139,000.

Other institutional investors have also recently bought and sold shares of the company. Roxbury Financial LLC acquired a new position in shares of AstraZeneca in the 2nd quarter valued at $29,000. Laurel Wealth Advisors LLC bought a new stake in shares of AstraZeneca in the third quarter worth about $30,000. GK Wealth Management LLC bought a new stake in shares of AstraZeneca in the third quarter worth about $31,000. Lynch Investment Planning LLC acquired a new stake in shares of AstraZeneca during the third quarter worth about $32,000. Finally, Resources Management Corp CT ADV acquired a new stake in shares of AstraZeneca during the first quarter worth about $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.7%

AZN opened at $174.20 on Friday. The stock has a market capitalization of $270.17 billion, a P/E ratio of 24.64, a P/E/G ratio of 1.43 and a beta of 0.24. AstraZeneca Plc has a 12 month low of $153.41 and a 12 month high of $212.71. The firm’s fifty day simple moving average is $170.72 and its 200 day simple moving average is $180.02. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51.

AstraZeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The firm had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same quarter last year, the business posted $2.38 EPS. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. As a group, research analysts anticipate that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Zacks Research upgraded AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating on the stock. Finally, CICC Research initiated coverage on shares of AstraZeneca in a report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 target price on the stock. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $206.67.

View Our Latest Stock Report on AstraZeneca

AstraZeneca Company Profile

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

See Also

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.